糖尿病心力衰竭中的血管新生作用——中医药治疗糖尿病心肌病的潜在靶点

临床上有充分证据表明，糖尿病与心力衰竭风险升高密切相关。糖尿病会加重心肌梗死后的舒张和收缩性心力衰竭，引发特异性心肌微血管并发症，即糖尿病心肌病。生物医学的新进展揭示了糖尿病与心血管异常之间的复杂联系及作用机制，包括能量代谢、血糖控制和血管生成等。基于整体观和辨证论治理论的中医药在糖尿病及其并发症的治疗上有着悠久的历史。文章采用生物反应信号网络分析，发现通过调节血管生成治疗糖尿病心力衰竭的潜在治疗靶点，并对一些治疗糖尿病、心力衰竭的常用中药相关基础研究进行总结，发现这些药物是治疗糖尿病心力衰竭中成药的重要组成，且活性成分可以作用于生物反应信号网络分析出的部分潜在治疗靶点，以此来阐述中药通过调节血管生成治疗糖尿病心力衰竭的可行性，为临床参考应用提供了一定证据支持。

The role of angiogenesis in diabetic heart failure:a potential target for Chinese medicine in the treatment of diabetic cardiomyopathy

There is strong clinical evidence that diabetes mellitus is closely associated with an increased risk of heart failure. Diabetes exacerbates diastolic and systolic heart failure after myocardial infarction,triggers an idiosyncratic myocardial microvascular complication,diabetic cardiomyopathy. New advances in biomedicine have revealed complex links and mechanisms of action between diabetes and cardiovascular abnormalities,including energy metabolism,glycaemic control and angiogenesis. Traditional Chinese medicine(TCM),based on a holistic view and dialectical theory of treatment,has a long history in the management of diabetes and its complications. This review uses bioresponse signalling network analysis to identify potential therapeutic targets for the treatment of diabetic heart failure through modulation of angiogenesis,and summarises some basic research related to TCM commonly used in the treatment of diabetes and heart failure. These drugs were found to be important components of proprietary TCM for the treatment of diabetic heart failure,and the active ingredients could act on some of the potential therapeutic targets identified by the bioresponse signalling network analysis,thus illustrating the feasibility of TCM for the treatment of diabetic heart failure through modulation of angiogenesis and providing some evidence to support the clinical reference application.